One of the main causes of peripheral arterial disease is smoking, which leads to the building up of plaque inside the arteries that carry oxygen rich blood. As per the data provided by World Health Organization in 2015, nearly 1.1 billion people were addicted to smoking. Moreover, increasing number of people are being diagnosed with high blood pressure, diabetes and other lifestyle related diseases on account of unhealthy dietary habits, growing pressure at work, etc. On the back of these factors, growth in pipeline of peripheral arterial disease therapeutics is anticipated over next few years.

Explore Report at: https://www.psmarketresearch.com/market-analysis/peripheral-arterial-disease-therapeutics-pipeline-analysis

According to the National Institute of Heart, Lung and Blood Institute, peripheral arterial disease is caused by formation of plaque in arteries, which can translocate to other organs such as head and limbs. Fat, cholesterol, calcium and other fibrous tissues are responsible for the formation of plaque, in turn resulting in, Atherosclerosis, a condition that transpires in plaque build-up. It also leads to hardening and narrowing of the arteries, which limits the supply of oxygen-rich blood to the body. It generally occurs in legs, but it can also occur in arteries that carry blood to the head, arms, kidney and stomach. Sometimes, blockage in blood flow can cause numbness and pain in that area of the body, in turn amplifying the chances of infection to the affected limbs and, in severe cases, it can cause gangrene.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/peripheral-arterial-disease-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of peripheral arterial disease therapeutics include Bayer AG, Juventas Therapeutics, Inc., Proteon Therapeutics, Inc., Humacyte, Inc., Veryan Medical Ltd., SurModics, Inc., Acotec Scientific Co., Ltd, Spectranetics Corporation, Cardionovum GmbH.